PRSS57
Serine protease 57
Also known as: PRS57_HUMAN, PRSSL1, UNQ782
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UWY2
- Gene
- PRSS57
- Ensembl
- ENSG00000185198
- Chromosome
- 19
- Canonical length
- 283 aa
- Protein class
- Enzymes, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes an arginine-specific serine protease and member of the peptidase S1 family of proteins. The encoded protein may undergo proteolytic activation before storage in azurophil granules, in neutrophil cells of the immune system. Following neutrophil activation, the protease is released into the pericellular environment, where it may play a role in defense against microbial pathogens. [provided by RefSeq, Jul 2016]
Canonical amino-acid sequenceUniProt
283 residues, UniProt reviewed canonical sequence.
>Q6UWY2|PRSS57
1 MGLGLRGWGR PLLTVATALM LPVKPPAGSW GAQIIGGHEV TPHSRPYMAS VRFGGQHHCG
61 GFLLRARWVV SAAHCFSHRD LRTGLVVLGA HVLSTAEPTQ QVFGIDALTT HPDYHPMTHA
121 NDICLLRLNG SAVLGPAVGL LRPPGRRARP PTAGTRCRVA GWGFVSDFEE LPPGLMEAKV
181 RVLDPDVCNS SWKGHLTLTM LCTRSGDSHR RGFCSADSGG PLVCRNRAHG LVSFSGLWCG
241 DPKTPDVYTQ VSAFVAWIWD VVRRSSPQPG PLPGTTRPPG EAALocalizationUniProt · AlphaFold · HPA
Whether an antibody against PRSS57 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 156 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 156 nTPM
- spleen: 1.5 nTPM
- lung: 0.5 nTPM
- thymus: 0.3 nTPM
- ovary: 0.2 nTPM
- adipose tissue: 0.1 nTPM
Single-cell type
- hematopoietic stem cells: 191 nCPM
- megakaryocyte-erythroid progenitors: 138 nCPM
- megakaryocyte progenitors: 66 nCPM
- thymocytes: 60 nCPM
- neutrophil progenitors: 58 nCPM
- monocyte progenitors: 37 nCPM
Immune cell
- basophil: 5.9 nTPM
- total PBMC: 3.5 nTPM
- memory CD8 T-cell: 3.1 nTPM
- NK-cell: 2.5 nTPM
- myeloid DC: 1.5 nTPM
- classical monocyte: 1.1 nTPM
Brain region
- hypothalamus: 0.2 nTPM
- cerebral cortex: 0.1 nTPM
- hippocampal formation: 0.1 nTPM
- medulla oblongata: 0.1 nTPM
- pons: 0.1 nTPM
- spinal cord: 0.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.71
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.61
- DepMap mean gene effect
- 0.11
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PRSS57 as an antibody target. Whether an autoantibody or antibody against PRSS57 could matter depends on whether native PRSS57 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PRSS57 is annotated as secreted, so native PRSS57 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PRSS57 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...